Mechanism of Action
CCK1 and CCK2 Receptor Signaling
CCK receptors are GPCRs that couple to Gq/G11, activating phospholipase C and raising intracellular calcium. CCK1 receptors on vagal afferent neurons transmit satiety signals to the brainstem nucleus tractus solitarius. CCK1 receptors on the gallbladder trigger contraction and bile release. CCK2 receptors in the brain modulate anxiety, pain, and satiety; in the stomach they stimulate gastric acid secretion from ECL cells via gastrin co-activation.
Digestive and Satiety Functions
Fat and protein in the duodenum stimulate I-cell CCK release, which simultaneously: (1) contracts gallbladder to release bile for fat emulsification; (2) stimulates pancreatic enzyme and bicarbonate secretion; (3) slows gastric emptying via pyloric contraction; (4) activates vagal afferents signaling satiety to the hypothalamus. This coordinated response matches digestive capacity to nutrient load while limiting meal size.
Research Summary
Satiety and Food Intake
Well EstablishedIV CCK infusion in humans reliably reduces meal size and hunger ratings in dose-dependent fashion. CCK1 receptor antagonists (devazepide, lorglumide) increase meal size, confirming endogenous CCK role in satiety. CCK acts synergistically with leptin/" class="wiki-internal-link">leptin and GLP-1 in integrated satiety network. CCK resistance (reduced CCK1 receptor sensitivity) is observed in obesity and may contribute to hyperphagia.
Anxiety and Panic
Active ResearchCCK-4 (tetrapeptide) is a potent panicogen in humans; IV CCK-4 reliably induces panic attacks in panic disorder patients and normal volunteers. CCK2 receptor antagonists show anxiolytic potential in animal models. Research explores CCK2 antagonism as treatment for panic disorder and general anxiety.
Pain Modulation
Active ResearchCCK2 receptors in the periaqueductal gray and spinal cord modulate opioid analgesia. CCK is anti-opioid: it reduces opioid effectiveness and may contribute to opioid tolerance. CCK2 antagonists potentiate opioid analgesia in animal models and have been explored for pain management. This anti-opioid mechanism makes CCK a target for improving opioid therapy.
Calculate your Cholecystokinin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Satiety/food intake research (human) | 0.5-4.0 CCK-8 units/kg/hour IV infusion | Single session | Intravenous infusion |
| Gallbladder/pancreatic function testing | Sincalide 0.02 mcg/kg IV over 3 minutes (diagnostic) | Single dose | Intravenous |
Exogenous CCK use is primarily research and diagnostic. Endogenous CCK is the primary physiological satiety signal responsive to dietary protein and fat.
Interactions
Safety Profile
Exogenous CCK infusion causes nausea, abdominal cramps, and urgency at higher doses. CCK-4 administration produces transient intense anxiety/panic reactions used diagnostically. Sincalide (CCK-8 analog) approved for diagnostic imaging may cause nausea, pain, and dizziness. No significant cardiovascular adverse effects at clinical doses. Endogenous CCK is well-tolerated as a physiological hormone with tight meal-coupled regulation.
References
- [1]Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol. 1973;84(3):488-495.
- [2]Degen L, et al. Effect of cholecystokinin on food intake in humans. Physiol Behav. 2001;73(3):411-416.
- [3]Bradwejn J, Koszycki D. Cholecystokinin and panic disorder. Pharmacol Biochem Behav. 1994;48(3):539-542.